Melanotan 2: A Research Guide for Australian Researchers

Melanotan 2 (MT-2) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It's one of the most frequently searched research compounds among Australian researchers — partly because of the country's high UV exposure, and partly because the published literature on MT-2 spans an unusually broad range of biological systems.

Mechanism

Native α-MSH binds five melanocortin receptors (MC1R through MC5R). Melanotan 2 is a non-selective agonist across most of these receptors, with particularly strong affinity at MC1R (pigmentation) and MC4R (appetite, sexual function). The non-selective binding profile is the reason MT-2 produces a broader pharmacologic effect than later, more selective analogues like bremelanotide (PT-141), which is MC4R-selective.

Lines of research

• Pigmentation: The most-studied effect. MC1R activation increases eumelanin synthesis in melanocytes. Animal and small human studies have measured tan response across various dosing protocols.
• Sexual function: MC4R activation is associated with pro-erectile and pro-libido effects in published trials. This line of research led directly to the development of bremelanotide as a more selective MC4R agonist.
• Appetite: MC4R activation suppresses appetite in published animal studies. Some human reports also describe reduced food intake during MT-2 use.

Half-life

Plasma half-life is ~33 hours, considerably longer than native α-MSH. Most research protocols use small, frequent subcutaneous doses with a loading phase, followed by a maintenance phase. Detailed dosing literature is on the MT-2 research guide.

Side-effect profile in published data

Commonly reported in trial and case-report data:

• Transient nausea, particularly after the first administrations.
• Facial flushing during peak plasma levels.
• Spontaneous erections in male subjects (MC4R-mediated).
• Darkening of existing moles — clinically relevant for long-term users.

The mole-darkening effect is worth particular attention in the Australian context. Researchers should be familiar with how MC1R activation alters melanocyte behaviour across all pigmented skin lesions, not just intended tanning targets.

Comparison with bremelanotide (PT-141)

Bremelanotide is the cleaved MT-2 metabolite and a much more MC4R-selective agonist. It has FDA approval (Vyleesi) for hypoactive sexual desire disorder. For the sexual-function research line, PT-141 has cleaner pharmacology and better human trial data. For pigmentation research, MT-2 remains the more relevant molecule.

Sourcing in Australia

Research-grade material is available via Melanotan 2 10mg, third-party tested. Reconstitution and storage detail is in our beginner's reconstitution guide.